Final results from Pfizer Inc.’s Covid-19 vaccine trial showed the company’s shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days.
BioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.
Many Covid-19 survivors are likely to be at greater risk of developing mental illness, psychiatrists said, after a large study found 20% of those infected with the coronavirus are diagnosed with a psychiatric disorder within 90 days.
An AstraZeneca executive said he felt encouraged by “incredibly promising” large-scale Covid-19 vaccine trial results unveiled by New York-based Pfizer and the company’s German partner BioNTech.
Late-stage trial results of a potential Covid-19 vaccine being developed by the University of Oxford and AstraZeneca could be presented in 2020 as the British government prepares for a possible vaccination rollout in late December or early 2021.
(Reuters) – AstraZeneca Plc said on Sunday Britain’s health regulator had started an accelerated review of its potential coronavirus vaccine. “We confirm the MHRA’s (Medicines and Healthcare Products Regulatory Agency) […]
Pfizer indicated that the company’s Phase III clinical trial of 44,000 volunteers with partner BioNTech needed less than 2,000 people to be fully enrolled.
The United States, Russia and France set new daily records for coronavirus infections as a second wave swelled across parts of the Northern Hemisphere, forcing some countries to impose new curbs.
Federal health regulators decided to allow the resumption of the U.S. trial of a leading Covid-19 vaccine candidate from AstraZeneca Plc and the University of Oxford, the Wall Street Journal reported, citing a person familiar with the matter and materials reviewed by it.
The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention presented details about Covid-19 and the requirements for a vaccine in a nine-hour virtual meeting.